Uitdehaag BM - Search Results

1

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Vennegoor A, et al. Among authors: uitdehaag bm. Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19. Mult Scler. 2013. PMID: 22992450

2

A study validating changes in the multiple sclerosis functional composite.

Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH. Hoogervorst EL, et al. Among authors: uitdehaag bm. Arch Neurol. 2002 Jan;59(1):113-6. doi: 10.1001/archneur.59.1.113. Arch Neurol. 2002. PMID: 11790238 Clinical Trial.

3

Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging.

Bot JC, Barkhof F, Lycklama à Nijeholt G, van Schaardenburg D, Voskuyl AE, Ader HJ, Pijnenburg JA, Polman CH, Uitdehaag BM, Vermeulen EG, Castelijns JA. Bot JC, et al. Among authors: uitdehaag bm. Radiology. 2002 Apr;223(1):46-56. doi: 10.1148/radiol.2231010707. Radiology. 2002. PMID: 11930047

4

Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.

de Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, Remarque EJ, Burgmans AC, Kalkers NF, Polman CH, Westendorp RG. de Jong BA, et al. Among authors: uitdehaag bm. J Neuroimmunol. 2002 May;126(1-2):172-9. doi: 10.1016/s0165-5728(02)00056-5. J Neuroimmunol. 2002. PMID: 12020968

5

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR, Hartung HP, Durelli L, Edan G, Fernández O, Seeldrayers P, Sørensen P, Margrie S, Rovaris M, Comi G, Filippi M; Early Treatment of Multiple Sclerosis Study Group. Barkhof F, et al. Among authors: uitdehaag bm. Ann Neurol. 2003 Jun;53(6):718-24. doi: 10.1002/ana.10551. Ann Neurol. 2003. PMID: 12783417 Clinical Trial.

6

CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis.

van Veen T, Crusius JB, van Winsen L, Xia B, Barkhof F, Salvador Peña A, Polman CH, Uitdehaag BM. van Veen T, et al. Among authors: uitdehaag bm. J Neuroimmunol. 2003 Jul;140(1-2):188-93. doi: 10.1016/s0165-5728(03)00184-x. J Neuroimmunol. 2003. PMID: 12864988

7

Cannabinoids and immune function.

Killestein J, Uitdehaag BM, Polman CH. Killestein J, et al. Among authors: uitdehaag bm. JAMA. 2003 Aug 13;290(6):754; author reply 755. doi: 10.1001/jama.290.6.754-b. JAMA. 2003. PMID: 12915426 No abstract available.

8

New and emerging treatment options for multiple sclerosis.

Polman CH, Uitdehaag BM. Polman CH, et al. Among authors: uitdehaag bm. Lancet Neurol. 2003 Sep;2(9):563-6. doi: 10.1016/s1474-4422(03)00505-2. Lancet Neurol. 2003. PMID: 12941579 Review.

9

A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy.

Polman CH, Jansen PH, Jansen C, Uitdehaag BM. Polman CH, et al. Among authors: uitdehaag bm. Neurology. 2003 Sep 9;61(5):719. doi: 10.1212/wnl.61.5.719. Neurology. 2003. PMID: 12963780 No abstract available.

10

Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.

Killestein J, Eikelenboom MJ, Izeboud T, Kalkers NF, Adèr HJ, Barkhof F, Van Lier RA, Uitdehaag BM, Polman CH. Killestein J, et al. Among authors: uitdehaag bm. J Neuroimmunol. 2003 Sep;142(1-2):141-8. doi: 10.1016/s0165-5728(03)00265-0. J Neuroimmunol. 2003. PMID: 14512173 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

419 results

Search Page